369.20
0.22%
Sharekhan
Biocon recently signed an exclusive licensing and supply agreement with Handok, a South Korean specialty pharma company for commercialization of synthetic liraglutide.
Promoters have decreased holdings from 60.64% to 54.45% in Jun 2025 qtr
More from Biocon Ltd.
Recommended